Sodium butyrate inhibits interferon-gamma induced indoleamine 2,3-dioxygenase expression via STAT1 in nasopharyngeal carcinoma cells

Life Sciences

Volumn 93, Issue 15, 2013, Pages 509-515

  He, Yu Wen ^a   Wang, Hong Sheng ^b   Zeng, Jun ^b   Fang, Xiefan ^c   Chen, Hong Yuan ^b   Du, Jun ^b   Yang, Xin Yun ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Indoleamine 2,3 dioxygenase; Sodium butyrate; STAT1

Indexed keywords

BUTYRIC ACID; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; STAT1 PROTEIN;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NASOPHARYNX CARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

INDOLEAMINE 2,3-DIOXYGENASE; SODIUM BUTYRATE; STAT1;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; BUTYRATES; CELL NUCLEUS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; NASOPHARYNGEAL NEOPLASMS; NF-KAPPA B; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 84885176242     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.07.028     Document Type: Article

References (33)

1. D. Bandyopadhyay, A. Mishra, and E.E. Medrano Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway Cancer Res 64 2004 7706 7710
2. G. Brandacher, A. Perathoner, R. Ladurner, S. Schneeberger, P. Obrist, and C. Winkler Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells Clin Cancer Res 12 2006 1144 1151
3. L. Catani, D. Sollazzo, S. Trabanelli, A. Curti, C. Evangelisti, and N. Polverelli Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia Ann Hematol 92 2012 67 78
4. J. Du, J. Zeng, X.L. Ou, X.D. Ren, and S.H. Cai Methylglyoxal downregulates Raf-1 protein through a ubiquitination-mediated mechanism Int J Biochem Cell Biol 38 2006 1084 1091
5. E. Faure, L. Thomas, H. Xu, A. Medvedev, O. Equils, and M. Arditi Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation J Immunol 166 2001 2018 2024
6. D.J. Gough, D.E. Levy, R.W. Johnstone, and C.J. Clarke IFNgamma signaling - does it mean JAK-STAT? Cytokine Growth Factor Rev 19 2008 383 394
7. B.F. Hinnebusch, S. Meng, J.T. Wu, S.Y. Archer, and R.A. Hodin The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation J Nutr 132 2002 1012 1017
8. D.Y. Hou, A.J. Muller, M.D. Sharma, J. DuHadaway, T. Banerjee, and M. Johnson Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses Cancer Res 67 2007 792 801
9. K.F. Hui, D.N. Ho, C.M. Tsang, J.M. Middeldorp, G.S. Tsao, and A.K. Chiang Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma Int J Cancer 131 2012 1930 1940
10. R.W. Johnstone, and J.D. Licht Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4 2003 13 18
11. J. Joseph, G. Mudduluru, S. Antony, S. Vashistha, P. Ajitkumar, and K. Somasundaram Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB Oncogene 23 2004 6304 6315
12. M. Jung, K. Hoffmann, and G. Brosch Analogues of trichostatin A and trapoxin B as histone deacetylase inhibitors Bioorg Med Chem 7 1997 1655 1658
13. J.B. Katz, A.J. Muller, and G.C. Prendergast Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape Immunol Rev 222 2008 206 221
14. Y.H. Kim, J.W. Park, J.Y. Lee, and T.K. Kwon Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells Carcinogenesis 25 2004 1813 1820
15. O.H. Kramer, and T. Heinzel Phosphorylation-acetylation switch in the regulation of STAT1 signaling Mol Cell Endocrinol 315 2010 40 48
16. O.H. Kramer, D. Baus, S.K. Knauer, S. Stein, E. Jager, and R.H. Stauber Acetylation of Stat1 modulates NF-kappaB activity Gene Dev 20 2006 473 485
17. O.H. Kramer, S.K. Knauer, G. Greiner, E. Jandt, S. Reichardt, and K.H. Guhrs A phosphorylation-acetylation switch regulates STAT1 signaling Gene Dev 23 2009 223 235
18. J.R. Lee, R.R. Dalton, J.L. Messina, M.D. Sharma, D.M. Smith, and R.E. Burgess Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma Lab Invest 83 2003 1457 1466
19. P. Liu, B.L. Xie, S.H. Cai, Y.W. He, G. Zhang, and Y.M. Yi Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes BMC Cancer 9 2009 2407 2416
20. A.J. Muller, J.B. DuHadaway, P.S. Donover, E. Sutanto-Ward, and G.C. Prendergast Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy Nat Med 11 2005 312 319
21. D.H. Munn, and A.L. Mellor Indoleamine 2,3-dioxygenase and tumor-induced tolerance J Clin Invest 117 2007 1147 1154
22. D.H. Munn, M.D. Sharma, D. Hou, B. Baban, J.R. Lee, and S.J. Antonia Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes J Clin Invest 114 2004 280 290
23. T. Nakamura, T. Shima, A. Saeki, T. Hidaka, A. Nakashima, and O. Takikawa Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer Cancer Sci 98 2007 874 881
24. C.A. Opitz, W. Wick, L. Steinman, and M. Platten Tryptophan degradation in autoimmune diseases Cell Mol Life Sci 64 2007 2542 2563
25. B. Pajak, and A. Orzechowski Sodium butyrate-dependent sensitization of human colon adenocarcinoma COLO 205 cells to TNF-alpha-induced apoptosis J Physiol Pharmacol 58 2007 163 176
26. S.P. Perrine, O. Hermine, T. Small, F. Suarez, R. O'Reilly, and F. Boulad A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies Blood 109 2007 2571 2578
27. L.C. Platanias Mechanisms of type-I- and type-II-interferon-mediated signalling Nat Rev Immunol 5 2005 375 386
28. C.M. Robinson, P.T. Hale, and J.M. Carlin NF-kappa B activation contributes to indoleamine dioxygenase transcriptional synergy induced by IFN-gamma and tumor necrosis factor-alpha Cytokine 35 2006 53 61
29. K. Schroder, P.J. Hertzog, T. Ravasi, and D.A. Hume Interferon-gamma: an overview of signals, mechanisms and functions J Leukoc Biol 75 2004 163 189
30. Z.Z. Si, K.G. Xiu, and Z. Yi Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma Int J Cancer 31 1983 587 590
31. S.R. Thomas, H. Salahifar, R. Mashima, N.H. Hunt, D.R. Richardson, and R. Stocker Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate J Immunol 166 2001 6332 6340
32. J. Zeng, S. Cai, Y. Yi, Y. He, Z. Wang, and G. Jiang Prevention of spontaneous tumor development in a ret transgenic mouse model by ret peptide vaccination with indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan Cancer Res 69 2009 3963 3970
33. X. Zhu, Z. Liu, B. Xie, Z. Li, G. Feng, and D. Yang EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells Cancer Lett 169 2001 27 32